News archive

To face the rising the problem of antibiotic resistance, UiT and other Norwegian universities are joining forces to educate the next generation of microbial experts. 

The new researcher school will be called MiMa: Microbiology Matters - novel approaches to tackle future health challenges. With fresh funding from the Norwegian Research Council, the school will educate infection biology scientist with a One Health perspective, including contagion between animals and humans - zoonotic diseases. 

The education will strengthen researchers' competence on preventing pandemics and the development of new medicines and vaccines. 

- We are all part of the same ecosystem. The COVID-19 pandemic was an example of how fast contagion can spread from animals to humans, and how this contagion can spread globally. By having knowledge about surveillance of other sources of contagion like domestic animals and wild game, we can prevent potential outbreaks or spread to humans, says associate professor Pauline Cavanagh from UiT.

Cavanagh will head the school together with professor Morten Kjos from the Norwegian University of Life Sciences (NMBU). 

MiMa: Microbiology Matters is a cooperative effort between UiT, The University of Oslo, The University of Bergen, NTNU in Trondheim, the Norwegian University of Life Sciences, OsloMet, and the University of Inland Norway. MiMa will also cooperate with industry and other Norwegian research institutions. 

Contact person at UiT

Associate professor Jorunn Pauline Cavanagh

Staphylococcus borealis has been found to be resistant to several different types of antibiotics, posing a potentially significant problem for the elderly.

In 2020, a research group at UiT The Arctic University of Norway in Tromsø discovered a previously unknown bacterium. You may have heard of Staphylococcus aureus (golden staph), but this one belongs to the white variety. 

The newcomer, discovered in Tromsø in Northern Norway, was proudly named Staphylococcus borealis (S. borealis) after the Northern Lights.

But how dangerous is it really, and is it a threat to us at all? 

33 Percent Antibiotic Resistance

To investigate, researchers collected bacterial samples stored in freezers at several Norwegian hospitals.

The samples went as far back as 2014, and the researchers conducted new tests to see if they could identify the new bacterium in the old samples. Meanwhile, new samples arriving at the UiT lab from 2020 to 2024 were tested continuously. In total, the researchers collected and analysed 129 samples from seven Norwegian hospitals.

It turns out that S. borealis is resistant to more than three different classes of antibiotics in one-third of the cases where it was tested. 

"We see the most resistance against the antibiotic classes fusidic acid, cephalosporins, penicillins, macrolides, and fluoroquinolones," explains Jorunn Pauline Cavanagh, who led the work on bacterial analyses.

Moreover, the bacterium also appears to be highly adept at acquiring protective mechanisms from other bacterial species. This means it could potentially develop antibiotic resistance quickly, when attacked with the medicines currently available.

A Problem for the Elderly

S. borealis is a bacterium that lives on our skin, and researchers have found that it can become problematic when your immune system is weakened. This makes it particularly concerning for the elderly and for those who have had knee or hip replacements. 

"This bacterium is an opportunist that can cause illness when your immune system is compromised. For example, we see that it can form what’s called biofilm around knee prostheses and cause infections that can be difficult to treat," explains Jorunn Pauline Cavanagh. 

Researchers are now working to determine which diseases this bacterium can cause. Preliminary findings suggest it may lead to urinary tract infections, as well as inflammation in areas where implants are present.

"We do know that it causes mastitis in dromedary camels. This is because we’ve published the bacterium’s genetic profile in international databases, which other researchers use to compare their own bacterial findings. So, more possibilities may emerge," says Cavanagh.

Contact Information

Jorunn Pauline Cavanagh
Associate professor at UiT The Arctic University of Norway
Phone: +47 40 49 84 90

Scientific Reference

https://journals.asm.org/doi/10.1128/spectrum.01988-24

POPULAR SCIENCE: Meet Staphylococcus aureus, the ultimate microscopic escape artist that invades, adapts, tricks, and thrives within our bodies.

As part of the larger global crisis of antimicrobial resistance (AMR), the bacterium Staphylococcus aureus represents a formidable challenge.

You might have heard about MRSA? This is the version that is resistant to the antibiotic Methicillin, and it is pushing modern medicine to its limits.

Infections with Staphylococcus aureus range from mild skin irritations to serious life-threatening diseases like pneumonia and bloodstream infections. This places it at center stage of the ongoing battle between microbes and medicine.

The invisible battle inside your body

Whether it’s dodging your immune system’s attacks or hijacking your cells’ energy, this microbe has evolved survival strategies that challenge our immune system and even our best antibiotics. The result is a brutal match between two hardcore players chasing each other inside your body.

On one side of this war is Staphylococcus aureus. On the other side is your strong immune system, constantly defending you.

But how does this tiny invader manage to outsmart such a powerful defence network as our immune system?

Read the whole story in Researcher's zone

Researchers from CANS and the research group Marbio have found antibacterial compounds in the Barents Sea, a new study shows.

During a research trip off Svalbard with the Norwegian research vessel FF Kronprins Haakon in 2020, UiT researchers came across actinobacteria in sediments and marine life. After laboratory analysis, the researchers have concluded that the bacteria contain compunds that disarm enteropathogenic E. coli bacteria, which is responsible for intestinal infections and infant mortality in developing countries. 

Read the news story in The National: 
https://www.thenationalnews.com/future/science/2024/08/30/how-the-arctic-could-unlock-secrets-of-antibiotic-resistance/

Download the scientific article from Frontiers in microbiology: 
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1432475/full

Contact information
Dr. Yannik Schneider
yannik.k.schneider@uit.no
https://uit.no/ansatte/yannik.k.schneider

The membrane is the bacteria’s most important line of defense against our antibiotics. When it sheds part of that defense, the discarded leftovers now prove to be key players in our fight against antibacterial resistance.

In the relentless battle against antibiotic resistance, scientists are continually seeking innovative strategies to combat drug-resistant infections. Today we found a clever way to study how antibiotics interact with bacteria, and the interesting part is that bacteria themselves gave us a hint on how to do it.

- Now we are making strides in tackling the antibacterial resistance crisis by developing new methods to understand how new antibiotics work, says researcher Maxim Bril'kov.

Read the whole story in the Research corner at uit.no

Doctors at The Helgeland Hospital Trust in Arctic Norway received test results two days earlier than before, when they tested a new way to analyze blood samples for suspected sepsis. This could mean life or death for patients at your local hospital.

Do you know anyone who has had sepsis? Chances are you do. In fact, every year some 49 million cases and 11 million sepsis-related deaths occurred worldwide in 2017, according to a study reported by the WHO. This accounts for 20 percent of all global deaths.

It goes without saying that it is crucial to get quick and accurate answers on which bacteria have entered the patient's blood, so that doctors can promptly administer the correct antibiotics to stop the infection. This is where two doctors from Northern Norway have confirmed a diagnostic breakthrough.

Important for small acute care hospitals

Hege Harboe-Sjåvik at Helgeland Hospital Trust and Kristoffer Hammer Endresen at Nordland Hospital Trust, in collaboration with CANS – Centre for New Antibacterial Strategies at UiT The Arctic University of Norway, examined a new analysis method for detecting bacteria in blood.

The BCID2 method was used at several smaller hospitals during the coronavirus pandemic to analyze COVID-19 tests, but it has not yet been used for rapid analysis of sepsis in Norway.

The doctors' goal was to check if this new and fast method works just as well at smaller hospitals, compared to sending samples for analysis at a large laboratory at a bigger hospital.

This would be a significant step in the right direction for faster and better patient treatment for suspected sepsis at local hospitals. It is important for smaller hospitals, which are often far from the large laboratories, to find out which bacteria are behind an infection so that they can more quickly administer the correct antibiotics.

Faster analyses - equally good results

The researchers reviewed the results from 160 blood samples with bacteria taken at Helgeland Hospital Trust in Mo i Rana, Sandnessjøen, and Mosjøen from July to December 2021. Rapid tests were performed at the various local hospitals, while the standard tests were carried out at a microbiological laboratory at the regional hospital in Bodø.

It turned out that the doctors in Helgeland both received the test results two days earlier than before, and they were almost as accurate as the tests done at the large laboratory in Bodø where the bacteria were cultured in the usual way.

The new method also revealed the possibility of providing better antibiotic treatment for the patient in one out of four cases.

“The conclusion is that this is a robust and accurate addition to traditional diagnostics for detecting bacteria in blood samples quickly. The method offers great potential for more targeted antibiotic use at local hospitals”, says Kristoffer Hammer Endresen.

“This is an innovative solution with great potential for better treatment and equitable services at local hospitals. Two days faster test results can have a significant impact on seriously ill patients at local hospitals. This can provide a more equitable patient service, without the need for patients or healthcare personnel to be moved between hospitals”, says Hege Harboe-Sjåvik at the Helgeland Hospital Trust.

"These are important findings for a growing patient group at local hospitals”, says Hege Harboe-Sjåvik.

“The results show great opportunities for more accurate antibiotic use, and that this is a tool with great potential to reduce unnecessary use of broad-spectrum antibiotics at local hospitals. This is important in the fight against antibiotic resistance”, explains Kristoffer Hammer Endresen at the Nordland Hospital Trust.

There were just under three percent of cases where the new test failed to detect the bacteria that were present in the blood. And there were no cases where the rapid test indicated the presence of bacteria in the blood when there actually were none, so-called false positives. 

References

"FilmArray (BCID2) provides essential and timely results in bloodstream infections in small acute care hospitals without conventional microbiology services"
https://onlinelibrary.wiley.com/doi/10.1111/apm.13374

WHO sepsis key facts:

https://www.who.int/news-room/fact-sheets/detail/sepsis 

Contact Information

Hege Harboe-Sjåvik
Medical Director, Helgeland Hospital Trust
hege.harboe-sjavik@helgelandssykehuset.no

Kristoffer Hammer Endresen
Senior Physician at the Diagnostic Clinic, Nordland Hospital Trust
kristoffer.endresen@nordlandssykehuset.no

Proper antibiotic use leads to less antibiotic resistance

To increase the chances of a patient's recovery, it is extremely important that the antibiotics given are effective against the bacteria that have invaded the body. However, it is not necessarily best to administer so-called broad-spectrum antibiotics that kill a wide range of bacteria, as this contributes to the development of antibiotic resistance.

Being able to target antibiotic treatment against the responsible bacteria as early as possible, while minimally affecting the beneficial bacteria in the body, is very important to ensure that antibiotics remain effective in the future.

Facts about antibiotic resistance

Antibiotic resistance occurs when bacteria change in a way that antibiotics can no longer kill them, making infections harder to treat. Overuse and misuse of antibiotics are two major reasons why bacteria develop resistance.

Antibiotic resistance is one of the greatest global threats to public health. New treatment options seem to be far off, and in the meantime, it is very important to implement multiple measures to slow down the development of resistance to the antibiotics we have today.

At CANS – Centre for New Antibacterial Strategies at UiT The Arctic University of Norway, research is being conducted on new ways to attack bacteria, how bacteria evolve, and how we should use antibiotics more responsibly. 

Facts about BCID2 and FilmArray

BCID2 is a type of test used to quickly determine which bacteria or yeast are present in the blood of patients who may have a bloodstream infection. BCID stands for BioFire Blood Culture Identification. The test is analyzed in a machine called FilmArray, and what is special about this test is that it can provide results very quickly – usually within an hour.

The test works by taking a small amount of the blood culture, that is, blood that has already shown signs of containing microbes, and examining it for genetic material (DNA or RNA) that is specific to different types of bacteria and yeast. It can also look for genes that may make the bacteria resistant to antibiotics.

Because the BCID2 test is so fast, it can help doctors choose the right antibiotics for treatment much earlier than traditional methods.

Using cancer drugs is necessary but may actually lead to more antibiotic resistance. It is a catch 22, but CANS researchers are about to uncover the extent of the problem – and the possible solutions.

As part of her PhD thesis, Jónína Guðmundsdóttir proved through experimental studies that the cancer drug Methotrexate opened the path for antibiotic resistance (AMR). 

Now, with fresh funding from the Northern Norway Regional Health Authority, she will take the project a big leap forward and further investigate the connection between AMR and a number of other cancer drugs. Starting now, she will be analysing at which concentrations, and in which combinations of drugs, those drugs become an AMR problem to look out for. 

- Building on data that I already collected for my PhD, when I tested 73 different cancer drugs against 11 different resistance genes in bacteria, we will finally be able to properly address the extent of the problem, researcher Jónína Guðmundsdóttir says.

The results will inevitably be highly relevant for the future treatment of cancer patients, who rely heavily on antibiotics to fight off infections when they go through surgery, chemotherapy, and radiation treatment.

Avoiding the catch 22

In proving which cancer drugs, or combinations of drugs, that can cause AMR, Guðmundsdóttir could be likely to come up with clinically relevant knowledge about which drugs to be careful with.

- If we can say that cancer treatment A leads to resistance to antibiotic B in bacteria, then clinicians could try to avoid treating patients undergoing treatment A with antibiotic B and rather go straight for antibiotic X that has the same effect, but where pre-existing AMR should not be a problem.

In three years from now, we should have a much clearer picture of which drugs are the drivers of this next to impossible catch 22 of cancer treatment:

For the benefit of the patients you are damned if you don’t use the drug, but when it comes to antibiotic resistance you may be damned if you do…

Contact information

Jónína Guðmundsdottir
Jonina.gudmundsdottir@uit.no

Phd thesis

Cancer drugs as drivers of antibiotic resistance
https://munin.uit.no/handle/10037/30482

Video: Cancer chemotherapy can lead to antibiotic resistance

We all know about DNA. It lives inside every cell in our bodies and shapes who we are and how we look. But what if we could use it as a tool against bacteria?

Creating new vaccines is one of several possible strategies in the fight against antibiotic-resistant bacteria, in addition to using less antibiotics and using them smarter. One of the bacteria that we still do not have vaccines against is Enterococcus faecium. It is often resistant to many common antibiotics, including a type of reserve antibiotic, or "last resort" antibiotic called Vancomycin. 

Patients who are hospitalized often have a weaker immune system and are particularly susceptible to infections with this bacterium. In addition, antibiotic resistance means that we increasingly no longer have effective medicine to help patients fight this bacterium. 

However, researchers from UiT The Arctic University of Norway and Ludwig Maximillians University in Germany have now found out how we can create an enterococcal vaccine that is relatively easy to produce. Having access to such a vaccine against antibiotic-resistant enterococci will be an important step in the fight against antibiotic resistance. 

Read the whole story in EurekAlert!

Infections with antibiotic-resistant bacteria are a growing global problem. Part of the solution may lie in copying the bacteria's own weapons. The research environment in Tromsø has found a new bacteriocin, in a very common skin bacterium. Bacteriocin inhibits the growth of antibiotic-resistant bacteria that are often the cause of disease and can be difficult to treat.

The fact that we have medicines against bacterial infections is something many people take for granted. But increasing resistance among bacteria means that more and more antibiotics do not work. When the bacteria become resistant to the antibiotics we have available, we are left without a treatment option for very common diseases. Over one million people die each year as a result of antibiotic resistance.

The first step in developing new antibiotics is to look for substances that inhibit bacterial growth.

Read the whole story in EurekAlert

Krigene i Ukraina og Gaza er brutale. Verst går det ut over sivilbefolkningen som blir drept, lemlestet og sendt på flukt. Men det finnes også andre alvorlige og usynlige konsekvenser av krigene - rask spredning av multiresistente bakterier. Les mer i Dagens Medisin

Rapporten fra NORM og NORM-VET som presenterer data om forekomst av antibiotikaresistens og forbruk av antibiotika til mennesker og dyr i 2022, er nå publisert.

Klikk her for å få tilgang til rapporten.

Read more about our projects, the CANS organization, outreach activites and our scientific publications.

Open and download the 2022 Annual Report here.

Welcome to CANS!

There are even more positives to probiotics than previously thought. As well as helping preterm babies gain a healthy gut microbiome, they reduce the chance of harmful bacteria building resistance to antibiotics.

Every year about 15 million preterm babies are born worldwide who suffer from a risk of infection and inflammation. Being born many weeks or even months before their expected due date, their immune system is less mature than in term babies, including impaired gut barrier function and quite different microbial community in the large intestine.

Giving antibiotics to preterm infants disrupts the maturing process of the gut microbiome, and makes them more vulnerable to antimicrobial resistant variants of harmful bacteria.

Researchers at UiT The Arctic University of Norway have found that probiotics help preterm babies achieve a better bacterial balance in the gut and eradicate harmful bacteria, as the under-developed gut microbiome works its way into maturity.  

Helping preterm babies catch up with their fellow newborns

The researchers behind the study used data from a clinical trial where stool samples were collected four times in the first year of life from 72 babies in six Norwegian neonatal intensive care units. They then divided the samples into groups depending on whether the newborns were given antibiotics, a combination of antibiotics and probiotics, or none. The microbial DNA in the samples was sequenced to follow the development of the babies’ gut microbiota.  

The study supports the findings of other recent studies showing that probiotics boost normal microbiota and maturation in preterm infants to levels comparable to full-term newborns.

Less antimicrobial resistance

But there is also another finding that should be very interesting to medical staff around the world fighting antimicrobial resistance, or AMR. With probiotics, the extremely preterm infants had decreased risk of carrying antimicrobial resistant bugs despite frequent treatment with antibiotics.

- We discovered that probiotic-supplemented preterm newborns have bacteria that carry substantially fewer antibiotic-resistance genes, than infants that did not get probiotic supplements, says doctoral research fellow Ahmed Bargheet, the first author of the study.

About the study

The study was carried out at the Pediatric Research Group for Infections and Host-Microbe Interaction Research Group at the Centre for New Antibacterial Strategies (CANS), UiT The Arctic University of Norway. The work was done in cooperation with the University Hospital of North Norway and funded by the Odd Berg Group, the Northern Norway Regional Health Authority and Tromsø Research Foundation. 

Scientific reference

“Development of early life gut resistome and mobilome across gestational ages and microbiota-modifying treatments”: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00178-0/fulltext 

Contact information

Ahmed Bargheet
Doctoral research fellow
https://en.uit.no/ansatte/person?p_document_id=745394

Veronika K. Pettersen
Associate professor
https://en.uit.no/ansatte/person?p_document_id=543168&p_dimension_id=88110

Claus Klingenberg
Professor and senior physician
https://en.uit.no/ansatte/person?p_document_id=41727&p_dimension_id=88116

Facts about probiotics

Probiotics are live bacteria and yeasts promoted as having various health benefits. They're usually added to yoghurts or taken as food supplements, and are often described as "good" or "friendly" bacteria: https://www.nhs.uk/conditions/probiotics/

The microbiome explained

Picture a bustling city on a weekday morning, the sidewalks flooded with people rushing to get to work or to appointments. Now imagine this at a microscopic level and you have an idea of what the microbiome looks like inside our bodies, consisting of trillions of microorganisms (also called microbiota or microbes) of thousands of different species: https://www.hsph.harvard.edu/nutritionsource/microbiome/

We have regular seminars presented by our team and research partners.

Stay updated about upcoming talks and join our mailing list.

To join the email list, please email lise.nordgard@uit.no

Thanks to all speakers and participants who all contributed to a great CANS day!

Kristin Hegstad og kollegene kikket inn i tarmbakteriens indre og avslørte hvorfor legenes siste utvei ikke ville fungert.

Les mer i Dagen Medisin, her!

Når vi har tatt imot krigsofre fra Ukraina, har vi sett at vi er godt rustet til å gi avansert medisinsk og kirurgisk behandling. Men det har også blottlagt vår sårbare antibiotikaberedskap.

Les mer i aftenposten - klikk her!

A PhD position in Computer Science is available at the Department of Computer Science affiliated with the Health Data Lab research group and Centre for New Antibacterial Strategies.

For more information about the position, click here!

Deadline of application: 6th December 2022

For further information about the position, contact Associate Professor Einar J Holsbø:

November the 18 is the European Antibiotic Awareness Day (EAAD).

You can already the day before follow a digital event hosted by European Centre for Disease and prevention and control (ECDC) with the theme:

"Preventing Antimicrobial Resistance Together"

     Click here for more information!

Gabriel Magno de Freitas Almeida has a nw publication on how Mucosal Environment Induces Phage Susceptibility in Streptococcus mutant!

For more information, click here!

Sybil has just published in the Researchers’ zone in Science Norway (the English version of forskning.no)

To read the whole article, click here!

Usage og Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway

This report, which is the twenty-first annual joint report from NORM and NORM-VET, presents data on resistance and usage for 2021.

REPORT

VETpodden: Gunnar skov Simonsen og Anne Merte Urdal presenterer hovedfunnene 

Earlier this month, Uppsala Antibiotic Center hosted a meeting with CANS and seven other AMR centers based in Norway, Sweden, Denmark and Finland.

The goal of the meeting was to discuss structure, work activities and possible collaborations between Nordic centers with an AMR focus, to hopefully strengthen the Nordic cooperation on AMR.

From CANS Arnfinn Sundsfjord, Klara Stensvåg and Lise Nordgård attended the meeting.

Antibiotikabruken i Norge har gått ned med en tredel på ti år. Les mer i Dagen Medisin

From publications to activities, get your annual CANS update here. 

Click here to download the 2021 annual report.

CANS-seminar with professor Nicholas Feasey from the Liverpool School of Tropical Medicine.

“Antimicrobial resistance is predicted to impact most heavily on sub-Saharan Africa, yet how much is really known about clinical outcomes from drug-resistant infection in this setting? I will present observational data from multiple clinical cohorts recruited from Queen Elizabeth Central Hospital, Blantyre, Malawi and the surrounding communities in the Southern Region of Malawi.

I will describe the burden of AMR and DRI in this setting and the distribution of extended spectrum beta-lactamase producing bacteria in humans, animals and the environment. Lastly I will consider approaches to tackling AMR in Southern Africa.”

Although antibiotics target bacteria, their common side effect is the outgrowth of gut fungi. The use of antibiotics in infancy is connected to the risk of allergic diseases later in life, but the underlying molecular mechanisms remain vague.

Associate professor Veronika K. Pettersen at UiT and CANS has recently reported the consequences of fungal overgrowth in a mice model. While gut bacteria primarily communicate with the immune system via metabolites, gut fungi seemed to modulate the host cells through direct cell contact and fungal proteins in particular.

"Our results suggest that an increased abundance of certain gut fungal species in early life may affect the developing intracellular attributes of epithelial and immune cells."

The results from the study show that antibiotic use can be catastrophic for the maturing immune system by damaging chemical communication between the gut bacteria and immune cells.

The study was done during Veronikas postdoc stay at the University of Calgary in Canada. The paper was published online on Biomedcentral on 22 February 2022.

Scientific reference
Metaproteomic profiling of fungal gut colonization in gnotobiotic mice (Biomedcentral)

"Introducing aspects of the work of a National Reference Centre". 

Presenter: Guido Werner, Department of infectious Diseases, Robert Koch Institut.

See the recording on Vimeo instead?

PhD Student  Jónína Sæunn Guðmundsdóttir has published her first articel in EBioMedicine  - Congratulations! 

Understanding drivers of antibiotic resistance evolution is fundamental for designing optimal treatment strategies and interventions to reduce the spread of antibiotic resistance. Various cytotoxic drugs used in cancer chemotherapy have antibacterial properties, but how bacterial populations are affected by these selective pressures is unknown. Here we test the hypothesis that the widely used cytotoxic drug methotrexate affects the evolution and selection of antibiotic resistance.

Read the full article here

Hittil har Norge sluppet unna høye antall dødsfall forårsaket av resistente bakterier. Det skyldes både hell og dyktighet, tror seksjonsoverlege Arnfinn Sundsfjord hos 20-årsjubilanten K-res.

Les hele artikkelen i Bioingeniøren, ved å klikke her!

Ekspertuttalelse i farmatid.no om betydningen av bakteriosiner som legemdiler og forskningen som gjøres ved NMBU.

Klikk her for å lese artikkelen.

In a new publication in Scientific Reports, Adriana Sanabrina, Jessin Janice, Erik Hjerde, Gunnar Skov Simonsen and Anne-Merethe Hanssen used shotgun-metagenomics to predict antibiotic resistance and virulence determinants in S. aureus from periprosthetic tissues.

Click here to read more!

The CAS Board of Directors has selected two Young CAS Fellow projects for the period of January 2022 to December 2023. Veronika Kuchařová Pettersen, associate professor at UiT The Arctic University og Norway (UiT), will lead the Young CAS fellow project: Infant Gut Microbiome Acquisition: Off to a Healthy Start.

Siden 2012 har det vært en markant nedgang i total antibiotikabruk i Norge. Tallene fra NORM 2020 viser en reduksjon på 32 prosent. Les hele artikkelen i Dagens Medisin

Fellesrapporten fra Veterinærinstitututtet og Folkehelseinstituttet for 2020 kan leses via FHIs hjemmesider. 

Congratulation to Christian Lentz, Veronika Kucharov Pettersen, Mona Johannessen, Pål Jarle Johnsen and Arnfinn Sundsfjord for receiving research funding from Helse Nord.

For more information click here.

Forskerne oppdaget bakterien ved en tilfeldighet. De skulle først og fremst studere hudbakterier som kan føre til alvorlige infeksjoner, spesielt hos fortidligfødte spedbarn.

Så dukket det en ny type bakterie opp i prøveglasset.

Forskerne har gitt den navnet Staphylococcus borealis fordi den er funnet i nord, og fordi den kan være tilpasset et nordlig klima.

Les forskning.no for mer om saken.

Et sammendrag av artikkelen kan også leses her.

Brage Larsen Sollund, distriktssjef i Kreftforeningen har sammen med Arnfinn Sundsfjord, leder for CANS, skrevet en kronikk i Nordnorsk debatt om viktigheten av forskningen som gjøres i CANS på antibiotikaresisten. Klikke her for å lese kronikken

Sybil Akua Okyerewa Obuobi is a postdoctoral fellow at the Department of Pharmacy and has received TFS starting grant for the project: 

COALITION: BaCteria respOnsive And intrinsicaLly active anTimIcrObial Nanohybrids

About CANS in LVS info, 2/2020: The research of several groups affiliated to CANS has been described in LVS info, medlemsblad 2/2020

Centre for New Antibacterial Strategies (CANS) receives attention in Norsk Farmaceutisk Tidsskrift: Forskere i nord samles til krig mot antibiotikaresistens

CANS - Tverrfaglig senter for nye antibakterielle strategier ved Norges universitet. NBS-nytt 03.08.2020, av Dr. scient Lise Nordgård, Prof. Klara Stensvåg (BFE), og Prof. Arnfinn Sundsfjord (Senterleder CANS).

Tromsø-forskere går foran i kampen mot en pandemi som er skumlere enn korona. Kronikk, Nordnorsk debatt, 23. November 2020, av Brage Larsen Sollund, distriktssjef i Kreftforeningen og Arnfinn Sundsfjord, leder for uiT`s Senter for nye antibakterielle strategier (CANS)

2020

Achten, N.B., Klingenberg, C., Plötz, F.B. (2020) Neonatal Early-Onset Sepsis Calculator and Antibiotic Therapy-Reply. JAMA Pediatr. 2020 May 1,174(5):508-509. doi:10.1001/jamapediatrics.2019.6269. PMID: 32150235 

Dretvik, T., Solevåg, A.L., Finvåg, A., Størdal ,E.H., Størdal, K., Klingenberg, C. (2020) Active antibiotic discontinuation in suspected but not confirmed early-onset neonatal sepsis-A quality improvement initiative. Acta Paediatr. 2020 Jun,109(6):1125-1130. doi: 10.1111/apa.15202. Epub 2020 Feb 15. PMID: 31999863 https://doi.org/10.1111/apa.15202

Elvebakk, A., Park, S.G., Haeng, C., Rämä, T. (2020) Psoroma capense and P. esterhuyseniae (Pannariaceae), two new alpine species from South                Africa. The Lichenologist 2020 ,Volum 52.(5) s. 345-352. https://doi.org/10.1017/S0024282920000377

Ezawa, T., Saito, R., Suzuki, S., Sugiyama, S., Sylte, I., Kurita, N. (2020) Protonation states of central amino acids in a zinc metalloprotease complexed with inhibitor: Molecular mechanics optimizations and ab initio molecular orbital calculations. Biophys Chem. 2020 Jun,261:106368. https://doi.org/10.1016/j.bpc.2020.106368

Ezawa ,T., Sugiyama, S., Ara, A., Sylte, I., Kurita, N. (2020) Design of galardine analogs as putative psudolysin inhibitors based on ab initiofragment molecular orbital calculations. J Biomol Struct Dyn. 2020 Jul,38(11):3307-3317. Epub 2019 Aug 29.PMID: 31422741 https://doi.org/10.1080/07391102.2019.1656672

Fellner, M., Lentz, C.S., Jamieson, S.A., Brewster, J.L., Chen, L., Bogyo, M., Mace, P.D. (2020) Structural Basis for the Inhibitor and Substrate Specificity of the Unique Fph Serine Hydrolases of Staphylococcus aureus. ACS Infect Dis. 2020 Oct 9,6(10):2771-2782. https://pubmed.ncbi.nlm.nih.gov/32865965/

Ferrand, R.A., McHugh, G., Rehman, A.M., Mujuru, H., Simms, V., Majonga, E.D., Nicol, M.P., Flaegstad, T., Gutteberg, T.J., Gonzalez-Martinez, C., Corbett, E.L., Rowland-Jones, S.L., Kranzer, K., Weiss, H.A., Odland, J.O., BREATHE Trial Group.(2020) Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial. JAMA Netw Open. 2020 Dec 1,3(12):e2028484. https://doi.org/10.1001/jamanetworkopen.2020.28484

Flygel, T.T., Sovershaeva, E., Claassen-Weitz, S., Hjerde, E., Mwaikono, K,S., Odland, J.Ø., Ferrand, R.A., Mchugh, G., Gutteberg, T.J., Nicol, M.P., Cavanagh, J.P., Flægstad, T., BREATHE Study Team. (2020) Composition of Gut Microbiota of Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection Taking Antiretroviral Therapy in Zimbabwe. J Infect Dis. 2020 Jan 14,221(3):483-492. https://doi.org/10.1093/infdis/jiz473

Fröhlich, C., Gama, J.A., Harms, K., Hirvonen ,V.H.A., Lund, B.A., van der Kamp, M.W., Johnsen, P.J., Samuelsen, Ø.,Leiros H.-K.S. (2020) Cryptic β-lactamase evolution is driven by low β-lactam concentrations. Submitted to Communications Biology, Jan 2021 https://doi.org/10.1101/2020.12.01.404343

Fröhlich, C., Sørum, V., Huber, S., Samuelsen, Ø., Berglund, F., Kristiansson, E., Kotsakis, S.D., Marathe, N.P., Larsson, D.G.J., Leiros, H.S.(2020) Structural and biochemical characterization of the environmental MBLs MYO-1, ECV-1 and SHD-1. J Antimicrob Chemother. 1,75(9):2554-2563. https://doi.org/10.1093/jac/dkaa175.

Gama, J.A., Kloos, J., Johnsen, P.J., Samuelsen, Ø. (2020) Host dependent maintenance of a blaNDM-1-encoding plasmid in clinical Escherichia coli isolates. Sci Rep. 9,10(1):9332. https://doi.org/10.1038/s41598-020-66239-8

Gama, J.A., Zilhão, R., Dionisio, F. (2020). Plasmid Interactions Can Improve Plasmid Persistence in Bacterial Populations. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2020.02033

Gama, J.A., Fredheim, E.G.A., Cléon, F., Reis, A.M., Zilhão, R., Dionisio, F. (2020). Dominance Between Plasmids Determines the Extent of Biofilm Formation. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2020.02070

Giordani, B., Basnet, P., Mishchenko, E., Luppi, B., Skalko-Basnet, N. (2020). Utilizing liposomal quercetin and gallic acid in localized treatment of vaginal Candida infections. Pharmaceutics 2020, Volum 12:9.(1) s. 1-21, https://doi.org/10.3390/pharmaceutics12010009

Goll, R., Johnsen, P.H., Hjerde, E., Diab, J., Valle, P.C., Hilpusch, F., Cavanagh, J.P. (2020) Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome. Gut Microbes. 2020 Nov 9,12(1):1794263. https://doi.org/10.1080/19490976.2020.1794263

Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F.I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., Krivec, U., Lo Vecchio, A., Shingadia, D., Soriano-Arandes, A., Melendo, S., Lanari, M., Pierantoni, L., Wagner, N., L'Huillier, A.G., Heininger, U., Ritz, N., Bandi, S., Krajcar, N,, Roglić, S., Santos, M., Christiaens, C., Creuven, M., Buonsenso, D., Welch, S.B., Bogyi, M,, Brinkmann, F., Tebruegge, M., ptbnet COVID-19 Study Group (Klingenberg C) (2020). COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep,4(9):653-661 https://doi.org/10.1016/S2352-4642(20)30177-2

Hagestad, O.C., Andersen, J.H., Altermark, B., Hansen, E., Rämä, T. (2020) Cultivable marine fungi from the Arctic Archipelago of Svalbard and their antibacterial activity. Mycology: An International Journal on Fungal Biology 2020, volume 11. (3). https://doi.org/10.1080/21501203.2019.1708492

Hansen, K.Ø., Hansen, I.K.Ø., Richard, C.S.M., Jenssen, M., Andersen, J.H., Hansen, Holst, E. (2020). Antimicrobial Activity of Securamines From the Bryozoan Securiflustra securifrons. Natural Product Communications 2021, Volum 16 (2). ISSN 1934-578X.s 1 - 8.s https://doi.org/10.3390/ijms21155460.

Hansen, I.K.Ø., Lövdahl, T., Simonovic, D., Hansen, K.Ø., Andersen, A.J.C., Devold, H., Richard, C.S.M. Andersen, J.H., Strøm, M.B. & Haug, T. (2020). Antimicrobial activity of small synthetic peptides based on the marine peptide turgencin A: prediction of antimicrobial peptide sequences in a natural peptide and strategy for optimization of potency. International Journal of Molecular Sciences, 21(15): 5460. https://doi.org/10.3390/ijms21155460.

Hansen, I.K.Ø, Isaksson, J., Poth, A.G., Hansen, K.Ø., Andersen, A.J.C., Richard, C.S., Blencke, H.M., Stensvåg, K., Craik, D.J. & Haug, T. (2020). Isolation and characterization of antimicrobial peptides with unusual disulfide connectivity from the colonial ascidian Synoicum turgens. Marine Drugs, 18(1):51. https://doi.org/10.3390/md18010051.

Hegstad, K., Mylvaganam, H., Janice, J.J., Josefsen, E., Sivertsen, A., Skaare, D. (2020). The role of horizontal gene transfer in the development of multidrug resistance in Haemophilus influenzae. mSphere 5:e00969-19. https://doi.org/10.1128/ mSphere.00969-19.

Hemmingsen, D., Mikalsen, C., Hansen, A.R., Fjalstad, J.W., Stenklev, N.C., Klingenberg, C. (2020) Pediatrics. Hearing in Schoolchildren After Neonatal Exposure to a High-Dose Gentamicin Regimen. 2020 Feb,145(2):e20192373. Epub 2020 Jan 8. PMID: 31915192 https://doi.org/10.1542/peds.2019-2373

Hira, J., Bentdal, S., Devold, H., Stensvåg, K. & Landfald, B. (2019) Vibrio echinoideorum sp. nov., isolated from an epidermal lesion on the test of a green sea urchin (Strongylocentrotus droebachiensis). International Journal of Systematic and Evolutionary Microbiology, 69(8):2277–2282. https://doi.org/doi:10.1099/ijsem.0.003462.

Hira, J., Uddin, J., Haugland, M.M., Lentz, C.S. (2020)From Differential Stains to Next Generation Physiology: Chemical Probes to Visualize Bacterial Cell Structure and Physiology. Molecules. 2020 Nov, 25(21): 4949.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663024/

Hira, J., Wolfson, D., Andersen, A.J.C., Haug, T. & Stensvåg, K. (2020). Autofluorescence mediated red spherulocyte sorting provides insights into the source of spinochromes in sea urchins. Scientific Reports, 10(1):1149 https://doi.org/http://dx.doi.org10.1038/s41598-019-57387-7.

Håkonsholm, F., Hetland, M.A.K., Svanevik, C.S., Sundsfjord, A. Lunestad, B.T., Marathe, N. P. (2020) Antibiotic Sensitivity Screening of Klebsiella spp. and Raoultella spp. Isolated from Marine Bivalve Molluscs Reveal Presence of CTX-M-Producing K. pneumoniae. Microorganisms. 2020 Dec, 8(12):1909.  https://doi.org/10.3390/microorganisms8121909

Jensen, V.V.S., Furberg, A-S., Slotved, H.S., Bazhukova, T., Haldorsen, B., Caugant, D.A., Sundsfjord, A., Valentiner-Branth, P., Simonsen, G.S. (2020) Epidemiological and molecular characterization of Streptococcus pneumoniaecarriage strains in pre-school children in Arkhangelsk, northern European Russia, prior to the introduction of conjugate pneumococcal vaccines. BMC Infect Dis. 2020, 20: 279. Published online 2020 Apr 15 https://doi.org/10.1186/s12879-020-04998-5

Johansen, T.B., Astrup, E., Jore, S., Nilssen, H., Dahlberg, B.B., Klingenberg, C., Berg, A.S., Greve-Isdah, l.M. (2020) Infection prevention guidelines and considerations for paediatric risk groups when reopening primary schools during COVID-19 pandemic, Norway, April 2020.Euro Surveill. 2020 Jun,25(22):2000921. PMID: 32524956 https://doi.org/10.2807/1560-7917.ES.2020.25.22.2000921

Jøraholmen, M.W., Bhargava, A., Julin, K., Johannessen, M., Skalko-Basnet, N. (2020) The Antimicrobial Properties of Chitosan Can be  Tailored by Formulation. Marine Drugs 2020 ,Volum 18., https://doi.org/10.3390/md18020096

Jøraholmen, M.W., Johannessen, M., Gravningen, K., Puolakkainen, M., Acharya, G., Basnet, P., Škalko-Basnet, N. (2020) Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection Pharmaceutics. 2020 Dec, 12(12): 1203. Published online 2020 Dec 11. https://doi.org/10.3390/pharmaceutics12121203

Jøraholmen, M.W., Bhargava, A., Julin, K., Johannessen, M., Škalko-Basnet, N. (2020) The Antimicrobial Properties of Chitosan Can Be Tailored by Formulation Mar Drugs. 2020 Feb, 18(2): 96. Published online 2020 Jan 31. https://doi.org/10.3390/md18020096

Keller, L.J., Lentz, C.S., Chen, Y.E., Metivier, R.J., Weerapana, E., Fischbach, M.A., Bogyo, M. (2020) Characterization of Serine Hydrolases Across Clinical Isolates of Commensal Skin Bacteria Staphylococcus epidermidisUsing Activity-Based Protein Profiling. ACS Infect Dis. 2020 May 8,6(5):930-938. https://doi.org/10.1021/acsinfecdis.0c00095

Klingenberg, C. (2020) Risk of bias in study on early antibiotics and necrotizing enterocolitis.J Pediatr. 2020 Jul 3:S0022-3476(20)30847-7. dOnline ahead of print. PMID: 32629011 https://doi.org/10.1016/j.jpeds.2020.07.004

Kunttu, P., Pasanen, H., Rämä, T., Kulju, M., Kunttu, S-A., Kotiranta, H. (2020). Diversity and ecology of aphyllophoroid fungi on driftwood logs on the shores of the Baltic Sea. Nordic Journal of Botany (NJB) 2020 Volum 38.(4). https://doi.org/10.1111/njb.02735

Lang, A., Klingenberg, C., Greve-Isdahl, M., Andresen, J.H. (2020) Neonates should be with their mothers, even if the mother has COVID-19. Tidsskr Nor Laegeforen. 2020 Mar 26,140(6). doi: 10.4045/tidsskr.20.0242. Print 2020 Apr 21. PMID: 32321214 

Lavizzari, A., Klingenberg, C., Profit, J., Zupancic, J.A.F., Davis, A.S., Mosca, F., Bearer, C.F., Roehr, C.C. (2020) Neonates in the COVID-19 pandemic. Molloy International Neonatal COVID-19 Consortium. Pediatr Res. 2020 Aug 3Online ahead of print. PMID: 32746446 doi: 10.4045/tidsskr.20.0242

Lavizzari, A., Klingenberg, C., Profit, J., Zupancic, J.A.F., Davis, A.S., Mosca, F., Molloy, E.J., Roehr, C.C. (2020)International comparison of guidelines for managing neonates at the early phase of the SARS-CoV-2 pandemic. International Neonatal COVID-19 Consortium. Pediatr Res. 2020 Jun 15. Online ahead of print. PMID: 32541844 https://doi.org/10.1038/s41390-020-0976-5

Leiros, H-K.S., Thomassen, A.M.,Samuelsen, Ø., Flach, C.F., Kotsakis, S.D., Larsson, D.G.J. (2020). Structural insights in to the enhanced carbapenemase efficiency of OXA-655 compared to OXA-10. FEBS Open Bio. 10(9):1821-1832. https://doi.org/10.1002/2211-5463.12935. Epub 2020 Aug 8.

Pain, M., Wolden, R., Jaén-Luchoro, D., Salvà-Serra, F., Iglesias, B.P., Karlsson, R., Klingenberg, C., Cavanagh, J.P. (2020)Staphylococcus borealis sp. nov., isolated from human skin and blood. Int J Syst Evol Microbiol. 2020 Dec,70(12):6067-6078. https://doi.org/10.1099/ijsem.0.004499

Paulsen, M.H., Ausbacher, D., Bayer, A., Engquist, M., Hansen, T., Haug, T., Anderssen, T., Andersen, J.H., Ericson Sollid, J.U. & Strøm, M.B. (2019). Antimicrobial activity of amphipathic α,α-disubstituted β-amino amide derivatives against ESBL – CARBA producing multi-resistant bacteria, effect of halogenation, lipophilicity and cationic character. European Journal of Medicinal Chemistry, 183:111671-111682. https://doi.org/10.1016/j.ejmech.2019.111671

Pedersen, T., Tellevik, M.G., Kommedal, Ø., Lindemann, P.C., Moyo, S.J., Janice, J., Blomberg, B., Samuelsen, Ø., Langeland, N. (2020). Horizontal plasmid transfer among Klebsiella pneumoniaeisolates is the key factor for dissemination of extended-spectrum β-lactamases among children in Tanzania. mSphere 15,5(4):e00428-20.  https://doi.org/10.1128/mSphere.00428-20

Pettersen, V.K., Arrieta, M.C. (2020) Host-microbiome intestinal interactions during early life: considerations for atopy and asthma development. Curr Opin Allergy Clin Immunol. 2020 Apr,20(2):138-148. doi: 10.1097/ACI.0000000000000629. PMID: 32004178

Rodríguez-Beltrán, J., Sørum, V., Toll-Riera, M., Vega, C. de la, Peña-Miller, R., Millán, Á.S. (2020)   Genetic dominance governs the evolution and spread of mobile genetic elements in bacteria. Proc Natl Acad Sci. 2020 Jul  7,117(27):15755–62. https://doi.org/10.1073/pnas.2001240117

Rørtveit, G., Simonsen, G.S. (2020). The Primary Care Perspective on the Norwegian National Strategy against Antimicrobial Resistance. Antibiotics (Basel) 2020 Sep, 9(9): 622.  https://doi.org/10.3390/antibiotics9090622

Samuelsen, Ø., Åstrand, O.A.H, Fröhlich, C., Heikal, A., Skagseth, S., Carlsen, T.J.O., Leiros, H-K.L., Bayer, A., Schnaars, C,, Kildahl-Andersen, G., Lauksund, S., Finke, S., Huber, S., Gjøen, T., Andresen, A.M.S., Økstad, O.A., Rongved, P. (2020) ZN148 – a modular synthetic metallo-β-lactamase inhibitor reverses carbapenem resistance in Gram-negative pathogens in vivo. Antimicrob Agents Chemother. 2020 May 21,64(6):e02415-19. https://doi.org/10.1128/AAC.02415-19. Print 2020 May 21.

Sanabria, A., Hjerde, E., Johannessen, M., Sollid, J.E., Simonsen, G.S., Hanssen, A-M. (2020). Shotgun-Metagenomics on Positive Blood Culture Bottles Inoculated With Prosthetic Joint Tissue: A Proof of Concept Study. Front Microbiol. 2020, 11: 1687. Published online 2020 Jul 17. https://doi.org/10.3389/fmicb.2020.01687

Schneider, Y. K-H., Jenssen, M., Isaksson, J., Østnes Hansen, K., Andersen, J.H., Hansen, E. (2020). Bioactivity of Serratiochelin A, a Siderophore Isolated from a Co-Culture of Serratia sp. and Shewanella sp.. Microorganisms 2020, Volum 8 (7). ISSN 2076-2607.s 1 - 17.s https://doi.org/10.3390/microorganisms8071042

Selvarajan, V., Obuobi, S.A.O, Pui, L., Rachel, E. (2020) Silica Nanoparticles—A Versatile Tool for the Treatment of Bacterial Infections. Frontiers in Chemistry 2020, Volum 8. (602)

Solstad, R.G., Johansen, C., Stensvåg, K., Strøm, M.B., Haug, T. (2020) Structure-activity relationship studies of shortened analogues of the antimicrobial peptide EeCentrocin 1 from the sea urchin Echinus esculentus. J. Pep. Sci. 2020,26:e3233. DOI:10.1002/psc.3233. https://doi.org/10.1002/psc.3233

Størdal, K., Bakken, I.J., Greve-Isdahl, M., Klingenberg, C., Helland, E., Nystad, W., Hjellvik, V., Gulseth, H.L. (2020) SARS-CoV-2 in children and adolescents in Norway: confirmed infection, hospitalisations and underlying conditions. Tidsskr Nor Laegeforen. 2020 Jun 24,140(11). doi: 10.4045/tidsskr.20.0457. Print 2020 Aug 18. PMID: 32815353

Ternullo, S., Schulte Werning, L., Holsæter, A.M., Skalko-Basnet, N. (2020). Curcumin-In-Deformable Liposomes-In-Chitosan Hydrogel as a Novel Wound Dressing. Pharmaceutics 2020 ,Volum 12.(1) https://doi.org/10.3390/pharmaceutics12010008

Thaulow, C.M., Lindemann, P.C., Klingenberg, C., Berild, D., Salvesen, B.H., Myklebust T.Å., Harthug, S. (2020) Epidemiology and Antimicrobial Susceptibility of Invasive Bacterial Infections in Children-A Population-Based Study From Norway. Pediatr Infect Dis J. 2020 Dec 24,Publish Ahead of Print. doi: 10.1097/INF.0000000000003013. Online ahead of print.PMID: 33298760

van Tilburg Bernardes, Pettersen, V.C., Gutierrez, M.W., Laforest-Lapointe, I., Jendzjowsky, N.G., Cavin, J-B., Vicentini, F.A., Keenan, C.M., Ramay, H.R., Samara, J., MacNaughton, W.K., Wilson, R.J.A., Kelly, M.M., McCoy,K.D.,  Sharkey, K.A.,  Arrieta, M-C. (2020) Intestinal fungi are causally implicated in microbiome assembly and immune development in mice Nat Commun. 2020, 11: 2577. Published online 2020 May 22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244730/

Vatne A, Klingenberg C, Øymar K, Rønnestad AE, Manzoni P, Rettedal S. Reduced Antibiotic Exposure by Serial Physical Examinations in Term Neonates at Risk of Early-onset Sepsis. Pediatr Infect Dis J. 2020 May,39(5):438-443. PMID: 32301920 https://doi.org/10.1097/INF.0000000000002590

Vimberg V, Cavanagh JP, Novotna M, Lenart J, Nguyen Thi Ngoc B, Vesela J, Pain M, Koberska M, Balikova Novotna G. Ribosome-Mediated Attenuation of vga(A) Expression Is Shaped by the Antibiotic Resistance Specificity of Vga(A) Protein Variants.Antimicrob Agents Chemother. 2020 Oct 20,64(11):e00666-20. Print 2020 Oct 20. PMID: 32816732 https://doi.org/10.1128/AAC.00666-20

Wirth, T., Bergot, M., Rasigade, J.P., Pichon, B., Barbier, M., Martins-Simoes, P., Jacob, L., Pike R., Tissieres, .P, Picaud JC, Kearns, A., Supply, P., Butin, M., Laurent, F., International Consortium for Staphylococcus capitis neonatal sepsis, ESGS Study Group of ESCMID (Klingenberg C) (2020) Niche specialization and spread of Staphylococcus capitis involved in neonatal sepsis. Nat Microbiol. 2020 May,5(5):735-745. Epub 2020 Apr 27. PMID: 32341568 https://doi.org/10.1038/s41564-020-0676-2

Wolden, R., Pain, M., Karlsson, R., Karlsson, A., Aarag Fredheim, E.G., Cavanagh, J.P. (2020) Identification of surface proteins in a clinical Staphylococcus haemolyticus isolate by bacterial surface shaving. BMC Microbiol. 2020 Apr 7,20(1):80. PMID: 3226483https://doi.org/10.1186/s12866-020-01778-8

Zykov, I.N., Frimodt-Møller, N., Småbrekke, L., Sundsfjord, A., Samuelsen, Ø. (2020) Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model. 2020 Feb,55(2):105851. https://doi.org/10.1016/j.ijantimicag.2019.11.008.

2019

Achten NB, Klingenberg C, Benitz WE, Stocker M, Schlapbach LJ, Giannoni E, Bokelaar R, Driessen GJA, Brodin P, Uthaya S, van Rossum AMC, Plötz FB. Association of Use of the Neonatal Early-Onset Sepsis Calculator With Reduction in Antibiotic Therapy and Safety: A Systematic Review and Meta-analysis. JAMA Pediatr. 2019, 173(11):1032-1040

Agyepong N, Govinden U, Owusu-Ofori A, Amoako DG, Allam M, Janice J, Pedersen T, Sundsfjord A, Essack S. Genomic characterization of multidrug-resistant ESBL-producing Klebsiella pneumoniae isolated from a Ghanaian teaching hospital. Int J Infect Dis. 2019; 85:117123. 

Cavanagh JP, Askarian F, Pain M, Bruun JA, Urbarova I, Wai SN, Schmidt F, Johannessen M. Proteome profiling of secreted and membrane vesicle associated proteins of an invasive and a commensal Staphylococcus haemolyticus isolate.  Data Brief. 2019 Jan 11;22:914-919. 

Granslo, Hildegunn Norbakken; Aarag, Elizabeth; Esaiassen, Eirin; Christophersen, Lars; Jensen, Peter Østrup; Mollnes, Tom Eirik; Moser, Claus; Flægstad, Trond; Klingenberg, Claus; Cavanagh, Jorunn Pauline. The synthetic antimicrobial peptide LTX21 induces inflammatory responses in a human whole blood model and a murine peritoneum model. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS) 2019 ;Volum 127.(6) s. 475483.

Hagestad, Ole Christian; Andersen, Jeanette hammer; Altermark, Bjørn; Hansen, Espen; Rämä, Teppo. Cultivable marine fungi from the Arctic Archipelago of Svalbard and their antibacterial activity. Mycology: An International Journal on Fungal Biology 2019. 

Jarlier, Vincent; Högberg, Liselotte Diaz; Heuer, Ole E.; Campos, Josó; Eckmanns, Tim; Giske, Christian G.; Grundmann, Hajo; Johnson, Alan P.; Kahlmeter, Gunnar; Monen, Jos; Pantosti, Annalisa; Rossolini, Gian Maria; van de Sande-Bruinsma, Nienke; Vatopoulos, Alkiviadis; Żabicka, Dorota; Žemličková, Helena; Monnet, Dominique L.; Simonsen, Gunnar Skov. Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016. Eurosurveillance 2019; Volum 24 (33). ISSN 1025-496X.s 1 - 10. 

Jøraholmen, May Wenche; Basnet, Purusotam; Tostrup, Mia Jonine; Moueffaq, Sabrin; Skalko-Basnet, Natasa. Localized Therapy of Vaginal Infections and Inflammation: Liposomes-InHydrogel Delivery System for Polyphenols. Pharmaceutics 2019; Volum 11 (2). ISSN 1999-4923.s 1 - 19.s 

Littmann J, Simonsen GS. Antimicrobial resistance is a super wicked problem. Tidsskr Nor Laegeforen. 2019 Oct 31;139(16).

Pain M, Hjerde E, Klingenberg C, Cavanagh JP. Comparative Genomic Analysis of Staphylococcus haemolyticus Reveals Key to Hospital Adaptation and Pathogenicity. Front Microbiol. 2019 Sep 10;10:2096.

Paulsen MH, Ausbacher D, Bayer A, Engqvist M, Hansen T, Haug T, Anderssen T, Andersen JH, Sollid, JUE, Strøm MB Antimicrobial activity of amphipathic α,α-disubstituted β-amino amide derivatives against ESBL–CARBA producing multi-resistant bacteria; effect of halogenation, lipophilicity and cationic character. European Journal of Medicinal Chemistry 2019 ;Volum 183. s. 111671-111682

Sanabria A, Røkeberg MEO, Johannessen M, Sollid JE, Simonsen GS, Hanssen AM. Culturing periprosthetic tissue in BacT/Alert® Virtuo blood culture system leads to improved and faster detection of prosthetic joint infections.  BMC Infect Dis. 2019 Jul 10;19(1):607. 

Solstad RG, Johansen C, Stensvåg K, Strøm MB, Haug T. Structure‐activity relationship studies of shortened analogues of the antimicrobial peptide EeCentrocin 1 from the sea urchin Echinus esculentus. Journal of Peptide Science 2019 ;Volum 26.(2), 

Sovershaeva E, Kranzer K, Mchugh G, Bandason T, Majonga ED, Usmani OS, Rowland-Jones S, Gutteberg T, Flægstad T, Ferrand RA, Odland JØ. History of tuberculosis is associated with lower exhaled nitric oxide levels in HIV-infected children. AIDS. 2019 Sep 1;33(11):1711-1718.

Svendsen, J.S.M., Grant, T.M., Rennison, D., Brimble, M.A., Svenson, J., Very Short and Stable Lactoferricin-Derived Antimicrobial Peptides: Design Principles and Potential Uses , Accounts of Chemical Research  2019, 52, 3, 749-759 

Syre, Heidi; Hetland, Marit; Bernhoff, Eva; Bollestad, Marianne; Grude, Nils; Simonsen, Gunnar Skov; Löhr, Iren Høyland. Microbial risk factors for treatment failure of pivmecillinam in community‐acquired urinary tract infections caused by ESBL‐producing Escherichia coli. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS) 2019. ISSN 0903-4641.s 1 - 10.s

Ternullo, Selenia; Gagnat, Eivind; Julin, Kjersti; Johannessen, Mona; Basnet, Purusotam; Vanić, Željka; Skalko-Basnet, Natasa. Liposomes augment biological benefits of curcumin for multitargeted skin therapy. European journal of pharmaceutics and biopharmaceutics 2019; Volum 144. ISSN 0939-6411.s 154 - 164.s

Vanic, Zeljka; Rukavina, Zora; Manner, Suvi; Fallarero, Adyary; Uzelac, Lidija; Kralj, Marijeta; Amidzic Klaric, Danijela; Bogdanov, Anita; Raffai, Timea; Virok, Deszo Peter; Filipovic-Grcic, Jelena; Skalko-Basnet, Natasa. Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections. International Journal of Nanomedicine 2019; Volum 14. ISSN 1176-9114.s 5957 - 5976.s 

Jonina Gudmundsdottir from the MicroPOP group has been selected by European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as  one of “30 outstanding scientists 30 years of age or younger” to celebrate the 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Paris this April. Selected articipants will actively participate on social media, especially Twitter, during the congress, and they are also invited to submit a scientific abstract for inclusion in the ECCMID 2020 Abstract Programme. The congress is expected to gather more than 13000 participants. Congratulations, Jonina.

https://www.eccmid.org/congress_information/30_under_30/

https://www.eccmid.org/